Accessibility StatementSkip Navigation TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights: Management Commentary "The first nin ...

Core Insights - Tilray Medical has formed a strategic partnership with Molteni, an Italian pharmaceutical firm, to enhance the availability of medical cannabis extracts for patients in Italy [1][2][3] - The collaboration aims to provide targeted education on medical cannabis therapies through Molteni's extensive network of healthcare professionals [2][3] Company Overview - Tilray Medical is a leader in the European medical cannabis market, with operations in Germany, Italy, Portugal, Poland, and the United Kingdom [3] - The company is dedicated to providing safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora [4] - Tilray has established itself as one of the largest suppliers of medical cannabis across 20 countries and five continents [4] Partnership Details - The partnership will leverage FL Group's regulatory and distribution capabilities alongside Molteni's scientific expertise to expand access to EU-GMP certified cannabis therapies [3] - The focus will be on empowering healthcare practitioners with knowledge and resources for effective pain management solutions [3] About Molteni - Molteni is a specialty pharmaceutical leader in therapeutic solutions for pain management and substance dependence, with operations in over 40 countries [8] - Founded in 1892 and headquartered in Florence, Italy, Molteni has its own manufacturing, R&D, regulatory, supply chain, and commercial capabilities [8]

Core Insights - Aurora Cannabis Inc. is launching its Whistler Cannabis Co. brand in Australia, expanding its global footprint and offering Australian patients access to premium Canadian cannabis products [1][2][3] - The company emphasizes its commitment to quality and patient care, leveraging its Canadian cultivation expertise to ensure consistent product quality [2][3] Product Launch Details - The first two products from Whistler Cannabis Co. to be introduced in Australia are Ginger Breath and Critical Diesel, both featuring high THC content [7] - Ginger Breath has a THC level of 32% and is an Indica strain, while Critical Diesel has a THC level of 28% and is a Sativa strain [7] Company Background - Aurora Cannabis Inc. is a leading global medical cannabis company headquartered in Edmonton, Alberta, with a diverse portfolio of brands serving both medical and consumer markets across multiple regions [4][5] - The company is recognized for its robust regulatory expertise and commitment to science and innovation, which supports its success in international markets [3][4]

Core Insights - Aurora Cannabis (ACB) is set to release its first-quarter fiscal 2026 results on August 6, with earnings estimated at 18 cents per share and revenues at $70.88 million, indicating a year-over-year earnings growth of 263.6% and a revenue increase of 5.4% [1][2] Financial Performance - The consensus for fiscal 2026 revenues is $272.1 million, reflecting a 7.6% year-over-year rise, while the EPS estimate is 56 cents, suggesting a 100% improvement year-over-year [2] - ACB has surpassed the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 50.10% [2] Market Dynamics - ACB's medical cannabis sales are expected to have increased in Germany and Australia, driven by new product launches, although regulatory disruptions in Poland and seasonal fluctuations may have impacted revenue growth [5][8] - The company has expanded its IndiMed portfolio in Australia, launching TEMPO 22 cultivars to meet rising patient demand, which is likely to enhance top-line growth [7] Operational Developments - ACB's recent $3 million upgrade to its Alpine facility in British Columbia has doubled yields and potency, potentially supporting top-line growth [10] - Despite a projected slight decline in first-quarter revenues compared to the previous quarter, margins are expected to remain robust due to a favorable product mix and cost discipline [11] Valuation and Stock Performance - Year-to-date, ACB shares have gained 5.4%, outperforming peers like Tilray Brands and Canopy Growth [12] - ACB trades at a forward 12-month P/S of 0.9, reflecting stronger growth expectations compared to Tilray Brands (0.65) and a lower valuation than Canopy Growth (1.07) [13]

Core Insights - Curaleaf Holdings, Inc. has opened a new medical cannabis dispensary in St. Augustine, Florida, increasing its store count to 68 in Florida and 154 nationwide [1][4] Group 1: Store Opening Details - The new dispensary is located at 1280 Ponce De Leon Blvd., St. Augustine, FL 32084, and will start serving medical patients on August 1, 2025 [1] - Curaleaf St. Augustine is strategically positioned near downtown shops, dining, and cultural attractions, enhancing accessibility for patients [2] Group 2: Product Offerings - The dispensary will offer a wide range of medical cannabis products, including the new Grassroots Dark Heart Collection, Select brand vapes and edibles, Florida-exclusive flower brand Reef, and Anthem pre-rolls [2][3] - Curaleaf has introduced a 72-hour Flower Satisfaction Guarantee for premium eighths purchased from Grassroots and Reef brands, allowing patients to return unsatisfactory products for store credit or exchange [3] Group 3: Company Commitment and Expansion - Curaleaf's Chairman and CEO, Boris Jordan, emphasized the company's commitment to enhancing flower quality and patient access to trusted products [3] - The grand opening celebration for Curaleaf St. Augustine is scheduled for August 8, 2025, featuring various activities to engage the community [4]